[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing",
    "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=e4279d8aa58156ac1977fcbfabb16b8f68dacbc964e9b1663745ec6589597ebb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748900707,
      "headline": "Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing",
      "id": 134968255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=e4279d8aa58156ac1977fcbfabb16b8f68dacbc964e9b1663745ec6589597ebb"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Gains 20% On $11.1 Billion Bristol Deal",
    "summary": "BNTX jumps 20% as BMY licenses PD-L1/VEGF-A bispecific antibody for solid tumors",
    "url": "https://finnhub.io/api/news?id=a835bd5bc5e1e7f15bd7cd4cf02173704e5af9fab3ef0d057a710ff0bb4cba60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748891921,
      "headline": "BioNTech Gains 20% On $11.1 Billion Bristol Deal",
      "id": 134968256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BNTX jumps 20% as BMY licenses PD-L1/VEGF-A bispecific antibody for solid tumors",
      "url": "https://finnhub.io/api/news?id=a835bd5bc5e1e7f15bd7cd4cf02173704e5af9fab3ef0d057a710ff0bb4cba60"
    }
  },
  {
    "ts": null,
    "headline": "Why BioNTech Stock Soared Today",
    "summary": "Bristol Myers Squibb just agreed to shower BioNTech with cash.",
    "url": "https://finnhub.io/api/news?id=ca461861cb54e49ce984fca705d84c4cbe0da1dbe8918db71c1a1f234e6a701a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748885926,
      "headline": "Why BioNTech Stock Soared Today",
      "id": 134955396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb just agreed to shower BioNTech with cash.",
      "url": "https://finnhub.io/api/news?id=ca461861cb54e49ce984fca705d84c4cbe0da1dbe8918db71c1a1f234e6a701a"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Sector Mixed; BioNTech Soars After Bristol Deal - Healthcare Roundup",
    "summary": "Healthcare Sector Mixed; BioNTech Soars After Bristol Deal - Healthcare Roundup",
    "url": "https://finnhub.io/api/news?id=d2c1972507d0ca1154f5695b40a5942a9ee4f0defdde4e38dc015dbddfcb7359",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748883240,
      "headline": "Healthcare Sector Mixed; BioNTech Soars After Bristol Deal - Healthcare Roundup",
      "id": 134983238,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Healthcare Sector Mixed; BioNTech Soars After Bristol Deal - Healthcare Roundup",
      "url": "https://finnhub.io/api/news?id=d2c1972507d0ca1154f5695b40a5942a9ee4f0defdde4e38dc015dbddfcb7359"
    }
  },
  {
    "ts": null,
    "headline": "BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug",
    "summary": "BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.",
    "url": "https://finnhub.io/api/news?id=7d04e011f4e7ec735be0749336184fc652f453dbfee62e637e29d1576163c716",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748880951,
      "headline": "BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug",
      "id": 134947653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.",
      "url": "https://finnhub.io/api/news?id=7d04e011f4e7ec735be0749336184fc652f453dbfee62e637e29d1576163c716"
    }
  },
  {
    "ts": null,
    "headline": "Trump's steel tariffs, Bristol Myers-BioNTech, sports bet tax",
    "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including the rally domestic steel companies are seeing after President Trump proposes a 50% steel tariff, Bristol Myers Squibb (BMY) licensing a cancer drug from BioNTech (BNTX), and Illinois lawmakers approving a tax hike on sports betting. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=057c4b1688ef8b6fcf46925a433c5e7734a15bba4ce77f27c3bfa5f7c5493e64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748880642,
      "headline": "Trump's steel tariffs, Bristol Myers-BioNTech, sports bet tax",
      "id": 134947655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including the rally domestic steel companies are seeing after President Trump proposes a 50% steel tariff, Bristol Myers Squibb (BMY) licensing a cancer drug from BioNTech (BNTX), and Illinois lawmakers approving a tax hike on sports betting. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=057c4b1688ef8b6fcf46925a433c5e7734a15bba4ce77f27c3bfa5f7c5493e64"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug",
    "summary": "A bold $11B bet, Chinese biotech roots, and a high-stakes race to dethrone Keytruda",
    "url": "https://finnhub.io/api/news?id=04267716dda244982040305d3346be8d75bd19155a33703c2bddc7e00a1f251f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748879740,
      "headline": "Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug",
      "id": 134947657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "A bold $11B bet, Chinese biotech roots, and a high-stakes race to dethrone Keytruda",
      "url": "https://finnhub.io/api/news?id=04267716dda244982040305d3346be8d75bd19155a33703c2bddc7e00a1f251f"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Steel Stocks Soar After Trump Doubles Steel Tariffs; Bristol Myers Squibb, BioNTech to Collaborate on Tumor Therapy",
    "summary": "All three major US stock indexes were down in late-morning trading after China refuted President Don",
    "url": "https://finnhub.io/api/news?id=c189948923c4cf765108f31dddaee8d0e5f141e0f512ac4d8926a723ff45d3ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748879156,
      "headline": "Top Midday Stories: Steel Stocks Soar After Trump Doubles Steel Tariffs; Bristol Myers Squibb, BioNTech to Collaborate on Tumor Therapy",
      "id": 134947660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were down in late-morning trading after China refuted President Don",
      "url": "https://finnhub.io/api/news?id=c189948923c4cf765108f31dddaee8d0e5f141e0f512ac4d8926a723ff45d3ef"
    }
  },
  {
    "ts": null,
    "headline": "M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal",
    "summary": "The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi (SNY, SAN.PA) is set to buy Blueprint Medicines (BPMC) for over $9 billion, while Bristol-Myers Squibb (BMY) plans to license a cancer drug from BioNTech (BNTX). BMO Capital Markets managing director of biopharma equity research Evan Seigerman comments on the M&A activity and regulatory oversight in the biopharma space. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=76483df8862d5bce7f3ad383c685c62d4e1081d00b6e475ae2226e1012d27a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748879100,
      "headline": "M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal",
      "id": 134944781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi (SNY, SAN.PA) is set to buy Blueprint Medicines (BPMC) for over $9 billion, while Bristol-Myers Squibb (BMY) plans to license a cancer drug from BioNTech (BNTX). BMO Capital Markets managing director of biopharma equity research Evan Seigerman comments on the M&A activity and regulatory oversight in the biopharma space. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=76483df8862d5bce7f3ad383c685c62d4e1081d00b6e475ae2226e1012d27a0b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Joins Pharma’s Hottest Horserace in $11.1B Deal With BioNTech",
    "summary": "Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.",
    "url": "https://finnhub.io/api/news?id=b7d942fd2d63c566448899c6372894371f9b18ddb03e77ca4d445cb347288570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748878740,
      "headline": "Bristol Myers Joins Pharma’s Hottest Horserace in $11.1B Deal With BioNTech",
      "id": 134947665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.",
      "url": "https://finnhub.io/api/news?id=b7d942fd2d63c566448899c6372894371f9b18ddb03e77ca4d445cb347288570"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration",
    "summary": "U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.",
    "url": "https://finnhub.io/api/news?id=67b4ac392e6cdbf4d62ed3de55602c623ea76a5d1968d218b98005ec85cf2e78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748873806,
      "headline": "BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration",
      "id": 134947666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.",
      "url": "https://finnhub.io/api/news?id=67b4ac392e6cdbf4d62ed3de55602c623ea76a5d1968d218b98005ec85cf2e78"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug",
    "summary": "BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate. Also Read: BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expa",
    "url": "https://finnhub.io/api/news?id=1afaede4ca7dae5441739443f1c29c91a4da938c002b0d0ed7cbd67a15b228f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748873656,
      "headline": "Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug",
      "id": 134947667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate. Also Read: BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expa",
      "url": "https://finnhub.io/api/news?id=1afaede4ca7dae5441739443f1c29c91a4da938c002b0d0ed7cbd67a15b228f4"
    }
  },
  {
    "ts": null,
    "headline": "Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal",
    "summary": "(Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B",
    "url": "https://finnhub.io/api/news?id=fac08862058836a0bd12c163076e9cee2ea5fb1809c3c3e4fe06c7034d5c8315",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748866028,
      "headline": "Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal",
      "id": 134937241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B",
      "url": "https://finnhub.io/api/news?id=fac08862058836a0bd12c163076e9cee2ea5fb1809c3c3e4fe06c7034d5c8315"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech soars 15% on cancer drug deal with Bristol Myers",
    "summary": "Investing.com -- Shares in BioNTech (NASDAQ:BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE:BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm on the development of an experimental cancer treatment, the U.S. pharmaceutical company announced on Monday.",
    "url": "https://finnhub.io/api/news?id=44c04c2729088a48ee8b5081227e8ef0c1f1e732b864da011b3d5dad8bb172bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748865881,
      "headline": "BioNTech soars 15% on cancer drug deal with Bristol Myers",
      "id": 134937310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares in BioNTech (NASDAQ:BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE:BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm on the development of an experimental cancer treatment, the U.S. pharmaceutical company announced on Monday.",
      "url": "https://finnhub.io/api/news?id=44c04c2729088a48ee8b5081227e8ef0c1f1e732b864da011b3d5dad8bb172bb"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb",
    "summary": "BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.",
    "url": "https://finnhub.io/api/news?id=99a0d539ce4d771e7232b795ad8ea744f40f7c7e979dfa6ae7974b3add162949",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748864520,
      "headline": "BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb",
      "id": 134944787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.",
      "url": "https://finnhub.io/api/news?id=99a0d539ce4d771e7232b795ad8ea744f40f7c7e979dfa6ae7974b3add162949"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration",
    "summary": "Investing.com -- BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental bispecific antibody BNT327, intended for use in various solid tumor types. The partnership aims to expedite and expand the development of this clinical candidate.",
    "url": "https://finnhub.io/api/news?id=6eb072429663eb786360561ee322b4e204c899d373250face4e09ecc83d78f9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748863274,
      "headline": "BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration",
      "id": 134937311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental bispecific antibody BNT327, intended for use in various solid tumor types. The partnership aims to expedite and expand the development of this clinical candidate.",
      "url": "https://finnhub.io/api/news?id=6eb072429663eb786360561ee322b4e204c899d373250face4e09ecc83d78f9c"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types",
    "summary": "MAINZ, Germany & PRINCETON, N.J., June 02, 2025--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody...",
    "url": "https://finnhub.io/api/news?id=0d54561af22d4ef4d93bfad4a09a83441874953670285def53c63b2c8cfbabe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748861100,
      "headline": "BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types",
      "id": 134937312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "MAINZ, Germany & PRINCETON, N.J., June 02, 2025--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody...",
      "url": "https://finnhub.io/api/news?id=0d54561af22d4ef4d93bfad4a09a83441874953670285def53c63b2c8cfbabe4"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748853960,
      "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "id": 134941480,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership",
    "summary": "U.S. drugmaker Bristol Myers Squibbannounced on Monday a $1.5 billion upfront payment topartner with Germany's BioNTech on anexperimental cancer drug, in a deal that could eventually exceed$11...",
    "url": "https://finnhub.io/api/news?id=668bb431db45f8c6a7beaac42d55587cf8ce54dc8c674f5d77a8a43c6c2a6b4a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748846789,
      "headline": "Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership",
      "id": 134935900,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "U.S. drugmaker Bristol Myers Squibbannounced on Monday a $1.5 billion upfront payment topartner with Germany's BioNTech on anexperimental cancer drug, in a deal that could eventually exceed$11...",
      "url": "https://finnhub.io/api/news?id=668bb431db45f8c6a7beaac42d55587cf8ce54dc8c674f5d77a8a43c6c2a6b4a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers allies with BioNTech on bispecific cancer drug",
    "summary": "The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.",
    "url": "https://finnhub.io/api/news?id=e161f7c047a2d7a9601f41485f9806288293a68aeb689d9be79c28e13d2defa2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748846700,
      "headline": "Bristol Myers allies with BioNTech on bispecific cancer drug",
      "id": 134937149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.",
      "url": "https://finnhub.io/api/news?id=e161f7c047a2d7a9601f41485f9806288293a68aeb689d9be79c28e13d2defa2"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)",
    "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.",
    "url": "https://finnhub.io/api/news?id=885497d646f1a667b5936603e9f671929a8bac6de68e81c01d6b5e5da0aa4648",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748835249,
      "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)",
      "id": 134937242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.",
      "url": "https://finnhub.io/api/news?id=885497d646f1a667b5936603e9f671929a8bac6de68e81c01d6b5e5da0aa4648"
    }
  }
]